ONEWORLD HEALTH FEATURED IN BBC WORLD DOCUMENTARY.

(Full text of a statement. Contact details below.)

OneWorld Health Featured in BBC World Documentary

Award-Winning BBC World Series "Kill or Cure?" to focus on Medicine for Kala-Azar

SAN FRANCISCO & NEW DELHI--(BUSINESS WIRE)--May 31, 2007--The Institute for OneWorld Health announced today that the story behind Paromomycin IM injection, its groundbreaking treatment for Visceral Leishmaniasis (VL) will be featured on BBC World's Kill or Cure? series on June 3. OneWorld Health is the first US-based non-profit pharmaceutical company that develops drugs for people with neglected diseases in the developing world.

The documentary, titled Kill or Cure? Visceral Leishmaniasis, will be previewed to members of the media on Thursday, May 31, 2007 at 5 pm at the 34th Annual International Conference on Global Health at the Omni Shoreham Hotel in Washington, DC.

"It is essential that the public and policy makers around the world know the story of how we developed a new formulation of an existing general use antibiotic, as a novel therapy for VL a lethal disease affecting the poorest of the poor," said OneWorld Health's James H. Hickman, Vice President, Communications & Fund Development. "Treatments accessible to poor and rural people are needed desperately for neglected diseases like visceral leishmaniasis. OneWorld Health's social entrepreneurial model that developed it represents 'proof of concept' for a new pathway of drug development."

The documentary revisits the story of 13-year-old Dilip, whom BBC World interviewed three years ago in his home state of Bihar in India. At that time, Dilip had been diagnosed with VL. If left untreated, VL is almost always fatal. With approximately 500,000 cases occurring annually VL, also known as kala-azar, is the world's second most deadly parasitic disease following malaria. Many of these cases occur in Bihar state.